TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA Share Price
Certificat
DE000SH8KZM4
| Delayed Deutsche Boerse AG 08:14:26 20/05/2024 BST | ||
| 1.27 EUR | +8.55% |
|
| Current month | -1.55% | ||
| 1 month | -51.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 20/05/24 | 1.27 | +8.55% |
| 17/05/24 | 1.17 | -4.10% |
| 16/05/24 | 1.22 | +18.45% |
| 15/05/24 | 1.03 | +6.19% |
| 14/05/24 | 0.97 | +10.23% |
Delayed Quote Deutsche Boerse AG
Last update May 20, 2024 at 08:14 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SH8KZM |
| ISIN | DE000SH8KZM4 |
| Date issued | 08/04/2022 |
| Strike | 13,110 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.62 € |
|---|---|
| Lowest since issue | 0.88 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
167.9
USD
Spread / Average Target
+9.24%
- Stock Market
- Certificates
- Certificat
